Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| BoneIndex02 | Other Identifier | Bone Index Finland Ltd. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| HealthPartners Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed for clinical validation of the novel ultrasound device (Bindex®, Bone Index Finland Ltd.). In a preliminary study technique has been validated in Finnish elderly woman population with 285 healthy and 56 osteoporotic subjects (n = 341 in total). Significant and good correlation was observed between Density Index (DI) determined with Bindex and femoral bone mineral density determined with DXA (r = 0.65 - 0.70). In addition, with determination of 90% sensitivity and specificity thresholds, significant number (65-75%) of patients could be diagnosed without additional verification with DXA.
First, the thresholds for DI will be determined by measuring 70 osteoporotic and 70 healthy patients (n = 140) with Bindex and DXA within four decades of age; age 50 to 59 years, age 60 to 69 years, age 70 to 79 years, and age 80 to 89 years. The feasibility of DI for diagnostics of osteoporosis and evaluation of bone mineral density (BMD) will be assessed. The thresholds for the BMD estimate obtained with DI will be determined for osteoporotic and non-osteoporotic patients. For fracture risk assessment, DI measurements are used to predict the outcome of currently available fracture risk assessment tools.
Data will be stored by Park Nicollet Institute. Only data listed below will be given to the research team at Bindex for analyses.
The data for determination of diagnostic threshold for DI in North American population will be analyzed by Bone Index Finland. The data will include following parameters:
Risk factors will be collected in a separate questionnaire (Appendix A).
Name
Medical Record Number
Weight (kg)
Height (cm)
Chair Stand test Can do easily; can do only with difficulty; cannot do
Risk Factors:
Previous fracture (Skeletal site, age at which fracture occured)
Parent fractured hip (Yes, No)
Current smoking (Yes, No)
Glucocorticoid Use (Yes, No)
Rheumatoid arthritis (Yes, No)
Alcohol 3 or more units per day (Yes, No)
Osteoporosis medication, type (e.g. alendronate, bisphosphonates), start- and end-date (Within the past five years)
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Thresholds for Bindex in Osteoporosis Diagnostics | Diagnostics thresholds for DI parameter for Osteoporosis within four decades of age; age 50 to 59 years, age 60 to 69 years, age 70 to 79 years, and age 80 to 89 years. | 1 year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Female (American-Caucasian)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John T Schousboe, MD, PhD | HealthPartners Institute | Principal Investigator |
| Janne P Karjalainen, PhD | Bone Index Finland Ltd | Study Director |
| Ossi Riekkinen, PhD | Bone Index Finland Ltd | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Park Nicollet Institute | Minneapolis | Minnesota | 55416 | United States |
Not provided
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| D004194 | Disease |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009750 |
| Nutritional and Metabolic Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |